MENLO PARK, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced that it received a positive jury trial verdict of $34 million associated with the patent infringement case it filed on September 16, 2021 against Alcon Inc., Alcon Vision, LLC, Alcon Research, LLC, and Ivantis, Inc.

加利福尼亚州门洛帕克，2024年4月29日（环球通讯社）--视力科学公司（Nasdaq:SGHT）（“视力科学”）是一家专注于开发和商业化创新介入技术以提高护理标准的眼保健技术公司，今天宣布，它收到了陪审团对其于2021年9月16日对Alcon Inc.，Alcon Vision，LLC，Alcon Research，LLC和Ivantis，Inc.提起的3400万美元专利侵权案的肯定判决。

(collectively, 'Alcon') in the U.S. District Court for the District of Delaware. Sight Sciences asserted that Alcon’s and Ivantis’ sale of the Hydrus® Microstent infringed three key patents..

（合称“Alcon”）在特拉华州美国地区法院。Sight Sciences声称，Alcon和Ivantis出售Hydrus®微型帐篷侵犯了三项关键专利。。

The verdict was announced on Friday, April 26, 2024, following a five-day jury trial. The jury found that Alcon willfully infringed all three Sight Sciences’ asserted patents and awarded monetary damages for past infringement. The monetary damages are comprised of $5.5 million in lost profits and $28.5 million in royalty damages for sales of the Hydrus Microstent for the period from its commercial launch through trial.

2024年4月26日，星期五，经过为期五天的陪审团审判，宣布了这一判决。陪审团发现，爱尔康故意侵犯了Sight Sciences声称的所有三项专利，并对过去的侵权行为给予了金钱赔偿。金钱损失包括550万美元的利润损失和2850万美元的特许权使用费赔偿金，用于从Hydrus Microstent商业发布到试用期间的销售。

The patents at issue were U.S. Patent Nos. 8,287,482, 9,370,443, and 11,389,328. The judge has not yet ruled on any potential enhancement of damages associated with the willfulness verdict or other remedies. Cooley LLP represented Sight Sciences. This verdict is subject to appeal..

争议的专利是美国专利号82874829370443和11389328。法官尚未就与故意判决或其他补救措施相关的损害赔偿可能增加作出裁决。Cooley LLP代表视觉科学。本判决可上诉。。

“Ever since Sight Sciences filed its first surgical glaucoma patent application in 2006, the Company has invested considerable capital in research and development to create new and innovative technologies, striving to pioneer novel treatments for chronic eye disease. Our commitment to these investments underscores our mission to expand patient access to transformative and interventional technologies, ultimately elevating the standard of care and enhancing patient outcomes,” said Paul Badawi, co-founder and CEO of Sight Sciences.

Sight Sciences联合创始人兼首席执行官保罗·巴达维（Paul Badawi）表示：“自2006年Sight Sciences首次申请青光眼手术专利以来，该公司在研发方面投入了大量资金，以创造新的创新技术，努力开创慢性眼病的新疗法。我们对这些投资的承诺突显了我们的使命，即扩大患者获得变革性和介入性技术的机会，最终提高护理标准，提高患者的治疗效果。”。

“Over the past eighteen years, we have pioneered various important and proprietary microinvasive surgical glaucoma methods and devices, including intracanalicular scaffolding, bladeless goniotomy, ab interno canaloplasty, ab interno trabeculotomy, and combinations of these methods. Given the substantial investments we have made in our surgical innovations on behalf of our surgeon customers and glaucoma patients, we believe safeguarding our intellectual property portfolio is paramount, and we are pleased with the jury’s verdict.

“在过去的十八年中，我们率先推出了各种重要且专有的微创青光眼手术方法和设备，包括管内支架术、无叶房角切开术、ab内管成形术、ab内小梁切开术以及这些方法的组合。鉴于我们代表外科医生客户和青光眼患者在手术创新方面所做的大量投资，我们认为保护我们的知识产权组合至关重要，我们对陪审团的裁决感到满意。

Our attention remains steadfast on equipping eye care providers with efficacious technologies and executing on our long-term growth strategy in surgical glaucoma and dry eye disease.”.

我们的注意力仍然坚定地致力于为眼科护理提供者提供有效的技术，并执行我们在外科青光眼和干眼症方面的长期增长策略。”。

About Sight Sciences

关于视觉科学

Sight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches.

Sight Sciences是一家眼科护理技术公司，专注于开发和商业化创新和介入解决方案，旨在改变护理并改善患者的生活。使用微创或非侵入性方法来针对世界上最普遍的眼病的根本原因，视觉科学试图创建更有效的治疗范例，以增强患者护理并取代传统的过时方法。

The Company’s OMNI® Surgical System is an implant-free glaucoma surgery technology (i) indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and (ii) CE Marked for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma.

该公司的OMNI®手术系统是一种无植入物青光眼手术技术（i），在美国用于降低成年原发性开角型青光眼患者的眼压；（ii）CE标记为Schlemm管的导管插入和腔内粘液扩张以及小梁网的切割，以降低成年开角型青光眼患者的眼压。

Glaucoma is the world’s leading cause of irreversible blindness. The SION® Surgical Instrument is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The Company’s TearCare® System is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (“MGD”), enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease.

青光眼是世界上不可逆失明的主要原因。SION®手术器械是一种无叶片的手动操作设备，用于眼科手术切除小梁网。该公司的TearCare®系统在美国已获得510（k）许可，可用于对因睑板腺功能障碍（“MGD”）引起的蒸发性干眼症成年患者进行局部热疗，从而使医生能够清除腺体阻塞，以解决干眼症的主要原因。

The Company’s SION® Surgical Instrument is a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. Visit sightsciences.com for more information..

该公司的SION®手术器械是一种手动操作的设备，用于眼科手术切除小梁网。有关更多信息，请访问sightsciences.com。。

Sight Sciences and TearCare are trademarks of Sight Sciences registered in the United States. OMNI and SION are trademarks of Sight Sciences registered in the United States, European Union and other territories. Hydrus is a registered trademark of Alcon Vision LLC.

Sight Sciences和TearCare是Sight Sciences在美国注册的商标。OMNI和SION是Sight Sciences在美国、欧盟和其他地区注册的商标。Hydrus是Alcon Vision LLC的注册商标。

For more information, visit www.sightsciences.com.

有关更多信息，请访问www.sightsciences.com。

© 2024 Sight Sciences. All rights reserved.

©2024视觉科学。保留所有权利。

Forward-Looking Statements

前瞻性声明

This press release, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which statements are subject to considerable risks and uncertainties.

本新闻稿以及本公司公开发布的其他声明和信息包含《1933年证券法》第27A节（经修订）和《1934年证券交易法》第21E节（经修订）所指的某些前瞻性声明，这些声明具有相当大的风险和不确定性。

The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and includes this statement for purposes of complying with these safe harbor provisions. Any statements made in this press release that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such.

公司打算将此类前瞻性声明纳入1995年《私人证券诉讼改革法案》中前瞻性声明的安全港条款，并将此声明包括在内，以遵守这些安全港条款。本新闻稿中所作的任何不属于历史事实的声明，包括关于我们的信念和期望的声明，都是前瞻性声明，应予以评估。

Forward-looking statements herein include, without limitation, statements concerning the disposition of the patent infringement case and its impact on our business and financial condition, including the final determination of damages, the amount and timing of other remedies, and the outcome of any appeal.

本文中的前瞻性陈述包括但不限于关于专利侵权案件的处理及其对我们的业务和财务状况的影响的陈述，包括最终确定的损害赔偿金、其他补救措施的金额和时间以及任何上诉的结果。

These statements often include words such as “anticipate,” “expect,” “suggests,” “plan,” “believe,” “intend,” “estimates,” “targets,” “projects,” “should,” “could,” “would,” “may,” “will,” “forecast” and other similar expressions. We base these forward-looking statements on our current expectations, plans and assumptions that we have made in light of our experience in the industry, as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate under the circumstances at such time.

这些陈述通常包括“预期”、“期望”、“建议”、“计划”、“相信”、“打算”、“估计”、“目标”、“项目”、“应该”、“可能”、“会”、“可能”、“会”、“会”、“预测”等词语以及其他类似的表达。我们根据行业经验做出的当前预期、计划和假设，以及我们对历史趋势、当前状况、预期未来发展和其他我们认为在当前情况下合适的因素的看法，做出这些前瞻性陈述。

Although management believes these forward-looking statements are based up.

尽管管理层认为这些前瞻性声明是基于。

Investor contact:

投资者联系人：

Philip Taylor

菲利浦泰勒

Gilmartin Group

吉尔马丁集团

415.937.5406

415.937.5406

Investor.Relations@Sightsciences.com

Investor.Relations@Sightsciences.com

Media contact:

媒体联系人：

pr@SightSciences.com

pr@SightSciences.com